Guggenheim Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price decreased by investment analysts at Guggenheim from $12.00 to $8.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 130.55% from the company’s previous close.

A number of other research firms have also weighed in on ZNTL. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday. Oppenheimer reissued an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a report on Monday, August 12th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Trading Down 12.2 %

Shares of NASDAQ ZNTL opened at $3.47 on Friday. The stock has a market capitalization of $247.27 million, a price-to-earnings ratio of -1.39 and a beta of 1.74. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07. The firm’s 50-day moving average price is $3.42 and its 200-day moving average price is $5.42.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities analysts predict that Zentalis Pharmaceuticals will post -2.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Decheng Capital LLC raised its holdings in shares of Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after buying an additional 970,859 shares during the last quarter. Verition Fund Management LLC increased its position in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after acquiring an additional 585,644 shares during the last quarter. Renaissance Technologies LLC lifted its position in Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares during the period. Finally, GSA Capital Partners LLP grew its stake in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.